Cabergoline therapy for cushing disease throughout pregnancy

Irene Woo, Robert M. Ehsanipoor

Research output: Contribution to journalArticle

Abstract

Background: Cushing disease during pregnancy is rare and is associated with significant maternal and fetal morbidity and mortality. Transsphenoidal pituitary surgery is the first-line therapy; however, in cases of failed surgery or in patients who are not surgical candidates, medical therapy has been used to control symptoms. Case: A 29-year-old woman with Cushing disease and a noncurative transsphenoidal pituitary surgery was successfully treated with cabergoline, a dopamine agonist. After approximately 1 year of therapy, she became pregnant. She was maintained on high-dose cabergoline throughout her pregnancy and had an uncomplicated antenatal course. She went into spontaneous labor at 38 weeks of gestation and delivered a healthy female neonate. Conclusion: Cabergoline can be used to manage Cushing disease successfully during pregnancy with an opportunity for a favorable outcome.

Original languageEnglish (US)
Pages (from-to)485-487
Number of pages3
JournalObstetrics and Gynecology
Volume122
Issue number2 PART2
DOIs
StatePublished - Aug 2013

Fingerprint

Pituitary ACTH Hypersecretion
Pregnancy
N,N-dimethyl-3,3-diphenyl-1-methylallylamine
Fetal Mortality
Dopamine Agonists
Therapeutics
Mothers
Newborn Infant
Morbidity
cabergoline

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Cabergoline therapy for cushing disease throughout pregnancy. / Woo, Irene; Ehsanipoor, Robert M.

In: Obstetrics and Gynecology, Vol. 122, No. 2 PART2, 08.2013, p. 485-487.

Research output: Contribution to journalArticle

Woo, Irene ; Ehsanipoor, Robert M. / Cabergoline therapy for cushing disease throughout pregnancy. In: Obstetrics and Gynecology. 2013 ; Vol. 122, No. 2 PART2. pp. 485-487.
@article{8651e0ae3a8e41d2a2e10e5e5ee86d51,
title = "Cabergoline therapy for cushing disease throughout pregnancy",
abstract = "Background: Cushing disease during pregnancy is rare and is associated with significant maternal and fetal morbidity and mortality. Transsphenoidal pituitary surgery is the first-line therapy; however, in cases of failed surgery or in patients who are not surgical candidates, medical therapy has been used to control symptoms. Case: A 29-year-old woman with Cushing disease and a noncurative transsphenoidal pituitary surgery was successfully treated with cabergoline, a dopamine agonist. After approximately 1 year of therapy, she became pregnant. She was maintained on high-dose cabergoline throughout her pregnancy and had an uncomplicated antenatal course. She went into spontaneous labor at 38 weeks of gestation and delivered a healthy female neonate. Conclusion: Cabergoline can be used to manage Cushing disease successfully during pregnancy with an opportunity for a favorable outcome.",
author = "Irene Woo and Ehsanipoor, {Robert M.}",
year = "2013",
month = "8",
doi = "10.1097/AOG.0b013e31829e398a",
language = "English (US)",
volume = "122",
pages = "485--487",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "2 PART2",

}

TY - JOUR

T1 - Cabergoline therapy for cushing disease throughout pregnancy

AU - Woo, Irene

AU - Ehsanipoor, Robert M.

PY - 2013/8

Y1 - 2013/8

N2 - Background: Cushing disease during pregnancy is rare and is associated with significant maternal and fetal morbidity and mortality. Transsphenoidal pituitary surgery is the first-line therapy; however, in cases of failed surgery or in patients who are not surgical candidates, medical therapy has been used to control symptoms. Case: A 29-year-old woman with Cushing disease and a noncurative transsphenoidal pituitary surgery was successfully treated with cabergoline, a dopamine agonist. After approximately 1 year of therapy, she became pregnant. She was maintained on high-dose cabergoline throughout her pregnancy and had an uncomplicated antenatal course. She went into spontaneous labor at 38 weeks of gestation and delivered a healthy female neonate. Conclusion: Cabergoline can be used to manage Cushing disease successfully during pregnancy with an opportunity for a favorable outcome.

AB - Background: Cushing disease during pregnancy is rare and is associated with significant maternal and fetal morbidity and mortality. Transsphenoidal pituitary surgery is the first-line therapy; however, in cases of failed surgery or in patients who are not surgical candidates, medical therapy has been used to control symptoms. Case: A 29-year-old woman with Cushing disease and a noncurative transsphenoidal pituitary surgery was successfully treated with cabergoline, a dopamine agonist. After approximately 1 year of therapy, she became pregnant. She was maintained on high-dose cabergoline throughout her pregnancy and had an uncomplicated antenatal course. She went into spontaneous labor at 38 weeks of gestation and delivered a healthy female neonate. Conclusion: Cabergoline can be used to manage Cushing disease successfully during pregnancy with an opportunity for a favorable outcome.

UR - http://www.scopus.com/inward/record.url?scp=84880933895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880933895&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e31829e398a

DO - 10.1097/AOG.0b013e31829e398a

M3 - Article

C2 - 23884269

AN - SCOPUS:84880933895

VL - 122

SP - 485

EP - 487

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2 PART2

ER -